Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-44274
Titel: Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
VerfasserIn: Rosar, Florian
Schuler, Joelle
Burgard, Caroline
Blickle, Arne
Bartholomä, Mark
Maus, Stephan
Petto, Sven
Khreish, Fadi
Schaefer, Andrea
Ezziddin, Samer
Sprache: Englisch
Titel: European Journal of Nuclear Medicine and Molecular Imaging
Bandnummer: 51
Heft: 13
Seiten: 4151-4162
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2024
Freie Schlagwörter: Rechallenge
PSMA
Radioligand therapy
177Lu
mCRPC
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Aim Rechallenge of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding this approach. In this study, we analyzed the efficacy and safety profile of one or more series of [177Lu]Lu-PSMA-617 RLT rechallenge in patients from a prospective registry (REALITY Study, NCT 04833517) after they initially benefited from PSMA-RLT. Methods Forty-seven patients with metastatic castration-resistant prostate cancer (mCRPC) who had biochemical response to initial [177Lu]Lu-PSMA-617 RLT followed by disease progression received at least one (up to three) series of [177Lu]LuPSMA-617 RLT rechallenge. Biochemical response rates based on prostate-specific antigen (PSA) serum value, PSA-based progression-free survival (PFS) and overall survival (OS) were calculated. Adverse events of the treatment were assessed according to ‘common terminology criteria for adverse events’ (CTCAE). Results After one series of RLT rechallenge, a PSA decline of at least 50% was achieved in 27/47 patients (57.4%). The median PFS of all patients was 8.7 mo and the median OS was 22.7 mo, each calculated from the administration of the first rechallenge series. Patients who responded (PSA decline>50%) to the rechallenge showed a median OS of 27.3 mo. Regarding PFS, a significant correlation (r=0.4128, p=0.0323) was found for these patients comparing initial and rechallenge RLT. Ten patients received a second and 3 patients received a third rechallenge series with 8/10 and 3/3 patients responding to repeated RLT rechallenge. No severe deterioration of adverse events rated by CTCAE criteria was observed. Conclusion [ 177Lu]Lu-PSMA-617 RLT rechallenge is associated with significant PSA response and encouraging survival outcome as well as a very favourable safety profile and should therefore be considered as a straight-forward treatment option in mCRPC patients, who previously benefited from PSMA-RLT.
DOI der Erstveröffentlichung: 10.1007/s00259-024-06825-4
URL der Erstveröffentlichung: https://doi.org/10.1007/s00259-024-06825-4
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-442748
hdl:20.500.11880/39572
http://dx.doi.org/10.22028/D291-44274
ISSN: 1619-7089
1619-7070
Datum des Eintrags: 4-Feb-2025
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Information
In Beziehung stehendes Objekt: https://static-content.springer.com/esm/art%3A10.1007%2Fs00259-024-06825-4/MediaObjects/259_2024_6825_MOESM1_ESM.docx
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Radiologie
Professur: M - Prof. Dr. Samer Ezziddin
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s00259-024-06825-4.pdf1,7 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons